Combination of anti-PD-1/anti-PD-L1 Antibodies Promotes Tumor Cell Phagocytosis By Bone Marrow Derived Dcs In A Murine Neuroblastoma Model

被引：0
|
作者：
Inoue, S. [1 ]
Horiuchi, Y. [2 ]
Takeuchi, Y. [1 ]
Murakami, T. [2 ]
Odaka, A. [1 ]
机构：
[1] Saitama Med Univ, Saitama Med Ctr, Dept Pediat Surg, Kawagoe, Saitama, Japan
[2] Saitama Med Univ, Dept Microbiol, Kawagoe, Saitama, Japan
来源：
PEDIATRIC BLOOD & CANCER | 2021年 / 68卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
PV0137
引用
收藏
页码：S218 / S219
页数：2
相关论文
共 50 条
  • [1] Combination of ANTI-PD-1/ANTI-PD-L1 Antibodies With the Distinct Character Exerts Preferable Anti-Tumor Immune Cycle in a Murine Neuroblastoma Model
    Inoue, S.
    Horiuchi, Y.
    Setoyama, Y.
    Takeuchi, Y.
    Murakami, T.
    Odaka, A.
    PEDIATRIC BLOOD & CANCER, 2020, 67 : S157 - S157
  • [2] Therapeutic uses of anti-PD-1 and anti-PD-L1 antibodies
    Philips, George K.
    Atkins, Michael
    INTERNATIONAL IMMUNOLOGY, 2015, 27 (01) : 39 - 46
  • [3] Toxicities of the anti-PD-1 and anti-PD-L1 immune checkpoint antibodies
    Naidoo, J.
    Page, D. B.
    Li, B. T.
    Connell, L. C.
    Schindler, K.
    Lacouture, M. E.
    Postow, M. A.
    Wolchok, J. D.
    ANNALS OF ONCOLOGY, 2015, 26 (12) : 2375 - 2391
  • [4] Hyperprogressive disease with anti-PD-1 and anti-PD-L1
    Brower, Vicki
    LANCET ONCOLOGY, 2016, 17 (12): : E527 - E527
  • [5] Anti-PD-1 and Anti-PD-L1 Monoclonal Antibodies in People Living with HIV and Cancer
    Lurain, Kathryn
    Ramaswami, Ramya
    Yarchoan, Robert
    Uldrick, Thomas S.
    CURRENT HIV/AIDS REPORTS, 2020, 17 (05) : 547 - 556
  • [6] ANTI-PD-1 AND ANTI-PD-L1 ANTIBODIES AS IMMUNOTHERAPY AGAINST CANCER: A STRUCTURAL PERSPECTIVE
    Cordova-Bahena, Luis
    Velasco-Velazquez, Marco A.
    REVISTA DE INVESTIGACION CLINICA-CLINICAL AND TRANSLATIONAL INVESTIGATION, 2021, 73 (01): : 8 - 16
  • [7] Anti-PD-1 and Anti-PD-L1 Monoclonal Antibodies in People Living with HIV and Cancer
    Kathryn Lurain
    Ramya Ramaswami
    Robert Yarchoan
    Thomas S. Uldrick
    Current HIV/AIDS Reports, 2020, 17 : 547 - 556
  • [8] Tusamitamab ravtansine induces immunogenic cell death and synergizes with anti-PD-1 or anti-PD-L1 antibody combination in solid tumor
    Nicolazzi, Celine
    Lefebvre, Anne-Marie
    Moindrot, Nicolas
    Larois, Christelle
    Classe, Marion
    Sidhu, Sukhvinder
    CANCER RESEARCH, 2024, 84 (06)
  • [9] Hypothalamic-Pituitary Autoimmunity in Patients Treated with Anti-PD-1 and Anti-PD-L1 Antibodies
    Bellastella, Giuseppe
    Carbone, Carla
    Scappaticcio, Lorenzo
    Cirillo, Paolo
    Troiani, Teresa
    Morgillo, Floriana
    Vietri, Maria Teresa
    Della Corte, Carminia Maria
    De Falco, Vincenzo
    Napolitano, Stefania
    Maiorino, Maria Ida
    De Bellis, Annamaria
    Esposito, Katherine
    CANCERS, 2021, 13 (16)
  • [10] Reorienting the immune system in the treatment of cancer by using anti-PD-1 and anti-PD-L1 antibodies
    Borch, Troels H.
    Donia, Marco
    Andersen, Mads H.
    Svane, Inge M.
    DRUG DISCOVERY TODAY, 2015, 20 (09) : 1127 - 1134
12345